{
  "thread": {
    "uuid": "63ddf0a289a677894bdedbc141c6379fd60ae281",
    "url": "https://finance.sina.com.cn/stock/aigc/ywsygs/2025-09-04/doc-infphyzr8854929.shtml",
    "site_full": "finance.sina.com.cn",
    "site": "sina.com.cn",
    "site_section": "https://finance.sina.cn",
    "site_categories": [
      "tech",
      "top_news_hk",
      "top_news_sg",
      "top_news_tw",
      "top_news"
    ],
    "section_title": "新浪财经_金融信息服务商",
    "site_title": null,
    "title": "烟台鲁银药业盐酸沙瑞环素片启动生物等效性试验 适应症为非结节性中度至重度寻常痤疮的炎症性病变|痤疮_新浪财经_新浪网",
    "title_full": "烟台鲁银药业盐酸沙瑞环素片启动生物等效性试验 适应症为非结节性中度至重度寻常痤疮的炎症性病变|痤疮_新浪财经_新浪网",
    "published": "2025-09-04T07:31:00.000+03:00",
    "replies_count": 0,
    "participants_count": 1,
    "site_type": "news",
    "country": "CN",
    "main_image": "",
    "performance_score": 0,
    "domain_rank": 236,
    "domain_rank_updated": "2025-06-03T00:00:00.000+03:00",
    "licensing_agency": [],
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "63ddf0a289a677894bdedbc141c6379fd60ae281",
  "url": "https://finance.sina.com.cn/stock/aigc/ywsygs/2025-09-04/doc-infphyzr8854929.shtml",
  "ord_in_thread": 0,
  "author": "小浪财讯",
  "published": "2025-09-04T07:31:00.000+03:00",
  "title": "烟台鲁银药业盐酸沙瑞环素片启动生物等效性试验 适应症为非结节性中度至重度寻常痤疮的炎症性病变|痤疮_新浪财经_新浪网",
  "text": "药物临床试验登记与信息公示平台数据显示，烟台鲁银药业有限公司的盐酸沙瑞环素片在健康参与者中随机、开放、两制剂、单次给药、两周期、双交叉空腹和餐后状态下的生物等效性试验已启动。临床试验登记号为CTR20253571，首次公示信息日期为2025年9月4日。\n该药物剂型为片剂，用法用量为每周期单次给药1次，每次1片，共2周期。本次试验主要目的为考察受试制剂和参比制剂在空腹及餐后状态下单次给药的药代动力学参数及相对生物利用度，评价两制剂是否具有生物等效性；次要目的为评价中国健康参与者单次空腹/餐后口服盐酸沙瑞环素片受试制剂和参比制剂后的安全性。\n盐酸沙瑞环素片为化学药物，适应症为9岁及以上患者非结节性中度至重度寻常痤疮的炎症性病变。寻常痤疮是毛囊皮脂腺的慢性炎症性皮肤病，表现为粉刺、丘疹、脓疱等，多发生于青少年，与雄激素水平、皮脂分泌增加等有关，诊断主要靠临床表现。\n本次试验主要终点指标包括Cmax、AUC0 - t、AUC0 - ∞；次要终点指标包括Tmax、t1/2、λz、AUC_%Extrap；不良事件，严重不良事件，伴随用药，临床实验室结果的改变（血常规、血生化、尿常规、凝血四项），临床症状，生命体征检查结果，12 - 导联心电图和体格检查结果。\n目前，该实验状态为进行中（尚未招募），目标入组人数56人。\n风险提示：市场有风险，投资需谨慎。本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验，因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联系biz@staff.sina.com.cn。",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "chinese",
  "sentiment": "positive",
  "categories": [
    "Health",
    "Social Issue",
    "Human Interest"
  ],
  "topics": [
    "Health->drug rehabilitation",
    "Health->health treatment and procedure",
    "Health->health organisation",
    "Social Issue->social services",
    "Social Issue->demographics"
  ],
  "ai_allow": true,
  "has_canonical": false,
  "breaking": true,
  "webz_reporter": false,
  "external_links": [],
  "external_images": [],
  "internal_images": [],
  "entities": {
    "persons": [],
    "locations": [],
    "organizations": []
  },
  "syndication": {
    "syndicated": null,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "trust": {
    "categories": [],
    "top_news": [
      "top_news_hk",
      "top_news_sg",
      "top_news_tw",
      "top_news"
    ],
    "bias": null,
    "source": {
      "type": null,
      "city": null,
      "state": null,
      "country": null,
      "domain_type": null,
      "agency": null,
      "organization_name": null
    }
  },
  "rating": null,
  "crawled": "2025-09-04T07:37:25.737+03:00",
  "updated": "2025-09-05T08:08:39.000+03:00"
}